Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Rheumatoid Arthritis Drugs Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the growth of the rheumatoid arthritis drugs market are the launch of new biosimilars, rising prevalence of arthritis, and an increase in the acceptance of biopharmaceuticals. The major factors that fuel the growth of the market are the rising incidence of rheumatoid arthritis and the increasing geriatric population. It usually affects the geriatric population, and the prevalence is seen higher in females as compared to males. Therefore, with the increasing geriatric population, the market is expected to experience growth in the coming years.
There are also several therapeutics and medications that have been developed in the recent years, to treat the symptoms of rheumatoid arthritis. Rheumatoid arthritis drugs management is generally associated with a high cost. Most commonly used drugs are disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic drugs. Thus biologics account for a prominent market share, in terms of revenue, due to the considerably high cost of these medicines. However the costs of rheumatoid arthritis drugs and NSAIDs are less than biologics. Thus, growing availability and awareness of safer drugs are anticipated to increase the global rheumatoid arthritis drugs market.
Scope of the Report
As per the scope of the report, rheumatoid arthritis is an autoimmune disorder that causes pain and inflammation in the joints of the body. Rheumatoid arthritis disease mostly affects the joints of the hand, wrists, elbows, knees, and ankles. It also affects the cardiac and respiratory system, and is known as systemic disease. It thus exhibits symptoms of swelling, redness, and warmth in the affected areas. Owing to the rise in the adoption of sedentary lifestyle, the patient pool is expected to witness a healthy growth.
Key Market Trends
NSAIDs Segment by Drug Class is Expected to be the Largest Segment During the Forecast Period
NSAIDs are being widely utilized for the symptomatic treatment of rheumatic disorders. DMARDs are also considered as the gold standard for the treatment of moderate to severe rheumatoid arthritis. Unlike conventional DMARDs, such as NSAIDs, which simply give symptomatic relief, biologic drugs are more efficient in the management of rheumatoid arthritis.
Asia-Pacific is Witnessing High Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia-Pacific market is projected to witness high growth during the forecast period, due to increasing healthcare expenditure. Moreover, the low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to the Asia-Pacific region from across the world. The increase in the incidence of rheumatoid arthritis disease is also expected to fuel the market in the region during the forecast period.
Competitive Landscape
A majority of rheumatoid arthritis drug products are being manufactured by key players. The market leaders in this industry have established their position in the market, and these manufacturers have a wide product range to offer and have an extensive distribution system across the world. Additionally, the emerging markets in the Asia-Pacific region are witnessing the entry of small players.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Launch of New Biosimilars
4.2.2 Rising Prevalence of Arthritis
4.2.3 Increase in the Acceptance of Biopharmaceuticals
4.3 Market Restraints
4.3.1 Patent Expiration of Blockbuster Drugs
4.3.2 Alternative Treatment Options
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Type of Molecule
5.1.1 Pharmaceuticals
5.1.2 Biopharmaceuticals
5.2 By Drug Class
5.2.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.2.2 Corticosteroids
5.2.3 Analgesics
5.2.4 Other Drug Classes
5.3 By Sales Channel
5.3.1 Prescription
5.3.2 Over-the-counter (OTC)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amgen Inc.
6.1.3 Bayer AG
6.1.4 Boehringer Ingelheim GmbH
6.1.5 Bristol-Myers Squibb Company
6.1.6 Celgene Corporation
6.1.7 F. Hoffmann-La Roche AG
6.1.8 Johnson & Johnson
6.1.9 Merck & Co. Inc.
6.1.10 Novartis AG
7. Market Opportunities and Future Trends
- By Type of Molecule
Pharmaceuticals
Biopharmaceuticals
By Drug Class
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Analgesics
Other Drug Classes
By Sales Channel
Prescription
Over-the-counter (OTC)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe - Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Chemoinformatics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 112 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 112 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the global chemoinformatics market include the innovations and advancements in the drug development process and increased demand of personalized medicine. The ever increasing growth of the drug development market is likely to boost the demand for chemoinformatics, owing to its numerous applications in drug designing at various stages. Right from target identification to its development as a potential drug candidate, chemoinformatics tools play a crucial part.
There has also been growing awareness related to personalized medicine, which has been driving the demand for effective medication, coupled with the unsustainable burden of chronic diseases. This serves as a compelling factor for new drug development, which promotes a positive impact on the growth of the global chemoinformatics market. These techniques find a vast array of applications in the various stages of drug designing. Furthermore, with the growing R&D intensity, the segment is further reinforced, owing to technological innovation inputs.
Scope of the Report
As per the scope of the report, chemoinformatics involves the application of computers to develop chemical data. With the help of chemoinformatics, study of chemical structures, and storage and analysis of the chemical data can be done easily. For the biological and pharmaceutical research organizations, visualization and analysis of data is necessary, and chemoinformatics helps in the management of such data. It is the use of computer and informational techniques applied to a range of problems in the field of chemistry.
Key Market Trends
Chemical Analysis Segment by Application is Expected to Grow Fastest During the Forecast Period
The chemical analysis segment accounted for the majority of the revenue share. The major factors that are contributing to the segment’s growth include the increasing investments in R&D and the relatively low success rate of the potential leads as drug molecules. The factors in conjunction with each other are expected to boost the usage of these platforms.
North America Holds the Largest Share and is Expected to Follow the Same Trend Over the Forecast Period
North America is likely to contribute to the largest share in the chemoinformatics market, owing to factors, such as enhanced healthcare of infrastructure, funds in initiatives of R&D, and technological enlargements in the United States and Canada. There has also been an increasing patient awareness about healthcare services and growing demand for personalized medicine that are likely to boost the market growth.
Competitive Landscape
The global chemoinformatics market has gained significant momentum in research institutions, pharmaceutical companies, biotechnology industry, research laboratories, and academic institutions. Therefore it is expected that over the course of time, there may be an influx of well-established players in the chemoinformatics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Innovations and Advancements in the Drug Development Process
4.2.2 Increased Demand of Personalized Medicine
4.3 Market Restraints
4.3.1 Cost Associated with Chemoinformatics Software
4.3.2 Lack of Skilled Labors
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Application
5.1.1 Chemical Analysis
5.1.1.1 Chemical Databases
5.1.1.2 Chemo metrics
5.1.1.3 Molecular Modelling
5.1.1.4 Other Chemical Analyses
5.1.2 Drug Discovery and Validation
5.1.2.1 High Throughput Screening
5.1.2.2 Lead Identification and Optimization
5.1.2.3 QSAR/QSPR
5.1.2.4 Other Drug Discovery and Validations
5.1.3 Virtual Screening
5.1.4 Other Applications
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Dassault Systemes
6.1.2 Agilent Technologies
6.1.3 Bio-rad Laboratories Inc.
6.1.4 BioSolveIT GmbH
6.1.5 Cerep Inc.
6.1.6 ChemAxon Inc.
6.1.7 Chemical Computing Group Inc.
6.1.8 Jubilant Biosys Inc.
6.1.9 Molecular Discovery Ltd
6.1.10 OpenEye Scientific Software
7. Market Opportunities and Future Trends
By Application
Chemical Analysis
Chemical Databases
Chemo metrics
Molecular Modelling
Other Chemical Analyses
Drug Discovery and Validation
High Throughput Screening
Lead Identification and Optimization
QSAR/QSPR
Other Drug Discovery and Validations
Virtual Screening
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Clinical Trial Management Systems Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The clinical trial management systems market was valued at USD 665.90 million in 2017. Although the market has been in its nascent stage for the last five years, it has currently established itself as a mature market in the North American region. Asia-Pacific is still experiencing a high growth rate, when compared to other regions. This is mainly attributed to increasing clinical trials due to the high availability of inexpensive resources and increasing population pool in these regions. Moreover, the increased adoption of clinical trial management systems in the past few years has been a major factor that is contributing to the growth of this market.
Europe is expected to register a CAGR of 14.12%, as many Europeans regions are still in the process of adopting these systems. Many companies that have developed clinical trial management systems have found a way to integrate with the existing software providers, in order to provide an efficient workflow in clinical trial management.
The increasing innovative technological advancements to curb the increasing costs associated with clinical trials has resulted in the development of the clinical trials management system. Although these systems have not been completely adapted due to various factors, the increasing awareness and the need to cut down additional costs associated with clinical trials are expected to drive the market in the coming years. Increasing R&D and the rise in the number of clinical trials in the Asian region are expected to further contribute to the growth of the market studied, during the forecast period.
Scope of the Report
The clinical trial management systems market (henceforth, referred to as market studied’) is segmented on the basis of delivery mode, components, end user, and type of system. Based on delivery, the market is sub-segmented into web-based clinical trial management system, on-premise clinical trial management system, and cloud-based clinical trial management system. By component, the market is sub-segmented into software, hardware, and services. By end user, the market is sub-segmented into pharmaceuticals, contract research organizations, and other end users. Based on the type, the market is sub-segmented into site-based clinical trial management system and licensed enterprise-based clinical trial management system.
Key Market Trends
Cloud-based Clinical Trial Management Systems sub-segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
Most big pharma and biotech companies are now increasingly adopting the cloud-based CTMS (clinical trial management systems). This increased adoption of cloud-based CTMS is because companies do not require to bear huge costs associated with the purchase of servers, and installation and validation of applications, and their maintenance. The new and advanced cloud-based CTMS facilitate the collaboration among the different groups at various sites to coordinate the successful completion of a trial.
BSI (Business Systems Integration AG) provides CTMS solution as a cloud or on-premise solution. Its functionality enhances the clinical trial operations from initial planning, implementation, reporting, patient monitoring, and entire documentation. Though data security is a typical challenge for cloud CTMS solution, most third-party providers have most advanced datacenters that require the users accessing the CTMS from outside company’s firewall to go through the authentication process. All the above factors are expected to contribute to sub-segment’s growth over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall clinical trial management systems market, with the United States emerging as the major contributor to the market. Factors, such as increasing R&D investments and rise in the demand for drug development, are aiding the growth of the market studied in the country. R&D budgets of the pharmaceutical companies have also increased in the last few years, owing to the increasing focus on regulating markets, complex molecules, and therapy segments. In the United States, pharmaceutical companies spend more money, time, and energy on R&D than others.
According to ClinicalTrials.gov, in 2017, 262,433 clinical trials were carried out worldwide, which increased to 285,679 trials in 2018. Whereas, in the United States, 115,123 studies were carried out. Thus, the rise in clinical trials in the region is expected to increase the demand for clinical trial management systems, which, in turn, is expected to aid the growth of the market studied in the United States, over the forecast period.
Competitive Landscape
The presence of major market players, such as Bio-Optronics Inc., MedNet Solutions Inc., Oracle, Parexel International Corporation, and IBM, is, in turn, increasing the overall competitive rivalry of the market. Large organizations rely heavily on advertising expenses and branding strategies, collaborations, initiatives or programs at national levels, which promote their product, and thus, get recognized earlier than other brands in the market. With the high prevalence rate of diseases, the intensity of competitive rivalry in the market is increasing over time.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Chronic Diseases and Lifestyle-related Disorders
4.2.2 Rise in Outsourcing of Clinical Trials and Implementation by Contract Research Organizations
4.2.3 Synchronization of Hospital Information System (HIS) with CTMS
4.3 Market Restraints
4.3.1 Data Security Issues
4.3.2 High Cost Associated with CTMS
4.3.3 Lack of Qualified and Skilled Labor to Handle CTMS
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Delivery Mode
5.1.1 Web-based Clinical Trial Management System
5.1.2 On-premise Clinical Trial Management System
5.1.3 Cloud-based Clinical Trial Management System
5.2 By Component
5.2.1 Software
5.2.2 Hardware
5.2.3 Services
5.3 By End User
5.3.1 Pharmaceuticals
5.3.2 Clinical Research Organization
5.3.3 Other End Users
5.4 By Type of System
5.4.1 Site-based Clinical Trial Management System
5.4.2 Licensed Enterprise-based Clinical Trial Management System
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 United Kingdom
5.5.2.2 Germany
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Bioclinica
6.1.2 Bio-Optronics Inc.
6.1.3 DATATRAK International Inc.
6.1.4 ERT Clinical
6.1.5 IBM
6.1.6 Medidata Solutions Inc.
6.1.7 MedNet Solutions Inc.
6.1.8 Oracle
6.1.9 Parexel International Corporation
6.1.10 ArisGlobal
7. Market Opportunities and Future Trends
By Delivery Mode
Web-based Clinical Trial Management System
On-premise Clinical Trial Management System
Cloud-based Clinical Trial Management System
By Component
Software
Hardware
Services
By End User
Pharmaceuticals
Clinical Research Organization
Other End Users
By Type of System
Site-based Clinical Trial Management System
Licensed Enterprise-based Clinical Trial Management System
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Companion Diagnostics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The growth of the global companion diagnostics market can be attributed to the rising focus on personalized medicine and co-development of drug and diagnostic technologies. In addition, rising cases of adverse drug reactions related to drugs, due to the lack of efficacy, drive the need for companion diagnostics. One of the major factors driving the growth of the companion diagnostics market is the increasing demand for personalized medicines and awareness about the same among the population. With companies increasing their collaborations for better biomarkers and diagnostics, in order to focus on cost regulations, there has been significant number of opportunities for its applications in indications, like cancer, cardiovascular and neurological disorders, etc.
Scope of the Report
Companion diagnostic tests provide information that is essential for the safe and effective use of a corresponding drug or biological product. As per the scope of the report, the market studied has been segmented by technology, indications, and geography. By technology, the market studied has been further segmented into immunohistochemistry, polymerase chain reaction, in-situ hybridization, real time-polymerase chain reaction, gene sequencing, and other technologies.
Key Market Trends
In-situ Hybridization (ISH) Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
In-situ hybridization (ISH), especially fluorescence in-situ hybridization (FISH), is a reliable, reproducible, sensitive, and accurate procedure, which is less affected by tissue fixation and analytical variables, in comparison to immunochemistry and other techniques. It offers the benefit of simultaneous evaluation of morphology and gene amplification. FISH has been the method of choice for use in companion diagnostics for several cancer therapies, such as trastuzumab, lapatinib, and criotinib, which have been already approved by FDA and other therapies, like everolimus, ridaforolimus, bicatulamide, TBD, and other drugs, that are yet to obtain regulatory approval.
The global market for in-situ hybridization in CDx is growing because of technological advancements, like the recent development of bright-field in-situ hybridization techniques, chromogenic in-situ hybridization (CISH), and the automated silver-enhanced in-situ hybridization (SISH) for the determination of gene status. Thus, considering the aforementioned factors, the ISH segment is expected to exhibit growth over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall companion diagnostics market, with the United States emerging as the major contributor to the market. The use of companion diagnostics is taking up a central role as an important treatment decision tool for a number of oncology drugs, which is also reflected in the way the FDA classifies these assays in relation to risk. In the United States, companion diagnostic assays are classified as IVD class III products, which represents a high-risk category, and consequently, the highest level of regulatory control. Hence, owing to high healthcare technology adoption rates and increasing demand for personalized medicine, the market for companion diagnostics in the United States is expected to register a substantial growth rate during the forecast period.
Competitive Landscape
The presence of major market players, such as Abbott, Agilent Technologies, F. Hoffmann-La Roche Ltd, Biomerieux SA, and Qiagen NV, is, in turn, increasing the overall competitive rivalry of the market. But the issues associated with the high development cost and poor reimbursement are affecting the market negatively. However, the rising focus of companies toward personalized medicine, co-development activities, and increased cases of adverse drug reactions is expected to boost the competitive rivalry in the market studied.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Companies Promoting Personalized Medicine and Targeted Therapy as a New Treatment Option
4.2.2 Increasing Cases of Adverse Drug Reactions
4.2.3 Co-development of Drug and Diagnostic Technology
4.3 Market Restraints
4.3.1 High Cost of Drug Development and Associated Clinical Trials
4.3.2 Reimbursement Issues among Many Countries
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Technology
5.1.1 Immunohistochemistry (IHC)
5.1.2 Polymerase Chain Reaction (PCR)
5.1.3 In-situ Hybridization (ISH)
5.1.4 Real-time PCR (RT-PCR)
5.1.5 Gene Sequencing
5.1.6 Other Technologies
5.2 By Indication
5.2.1 Lung Cancer
5.2.2 Breast Cancer
5.2.3 Colorectal Cancer
5.2.4 Leukemia
5.2.5 Melanoma
5.2.6 Other Indications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Abbott
6.1.2 Agilent Technologies Inc.
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Biomerieux SA
6.1.5 Qiagen NV
6.1.6 Siemens Healthcare
6.1.7 Thermo Fisher Scientific Inc.
6.1.8 Danaher Corporation (Beckman Coulter Inc.)
7. Market Opportunities and Future Trends
By Technology
- Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Other Technologies
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Melanoma
Other Indications
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe - Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
e-Health Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of e-health market include the growth in IoT and technological innovations, rising preference toward mobile technology and internet, and rising demand for population health management. Lifestyle-associated disorders, such as hypertension and diabetes, are expected to increase over the forecast period. These diseases raise the blood pressure and blood sugar levels. Thus, the increasing awareness among people about e-health and rising acceptance level among healthcare professionals, coupled with evidence of the efficiency of using this technology, are anticipated to result in substantial growth for this industry.
In recent years, the number of applications for internet in healthcare has increased exponentially. With the help the internet, healthcare professionals can deliver health information to health consumers more conveniently and in less time. Right from recording the patient entry to discharge, everything is being recorded with the help of the internet. IoT is propelling the market growth majorly in personal e-Health. IoT brings ease and convenience for healthcare providers, as well as for end users. Hence the adoption rate of incorporating it in healthcare is ever increasing, especially in developed countries.
Scope of the Report
As per the scope of the report, e-health is a promising field in public health and business, medical informatics, referring to health services, and information delivered or improved through the internet and related technologies. It empowers patients to take an active role in their treatment, allowing them to gain a deeper understanding of their conditions and how to effectively manage them.
Key Market Trends
Electronic Health Records (EHR) Segment is Expected to Grow the Fastest During the Forecast Period
EHR has been found dominating the overall market, which can be attributed to the growing adoption rate of EHR by many developed and developing countries, globally. EHR also improves the healthcare quality and offers convenience for healthcare providers, in terms of quick access to patient records, improved decision support, provides clinical alerts, and real-time quality reporting. These benefits have thus, contributed to the growth of EHR worldwide.
North American Region Holds the Largest Market Share and is Expected to Follow the Same Trend Over the Forecast Period
North America is expected to be the largest market, due to the presence of technologically updated population base and various current initiatives taken in the region. These aforementioned factors are expected to be the drivers for the market growth. The high growth of this region has also been attributed to the availability of high-tech healthcare infrastructure, along with high-speed internet. Thus the rising awareness is expected to contribute substantially toward the development of the overall market.
Competitive Landscape
The rising focus of the players on technological developments and innovation is expected to fuel the growth of the overall market in the coming few years. As per the study, the competitive scenario of the global e-Health market is likely to intensify with an increasing number of players in the near future.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growth in IoT and Technological Innovations
4.2.2 Rising Preference Toward Mobile Technology and Internet
4.2.3 Rising Demand for Population Health Management
4.3 Market Restraints
4.3.1 Concerns over Data Security
4.3.2 Lack of Reimbursement Policies in the Emerging Markets
4.3.3 Lack of Proper Infrastructure for e-Health in Emerging Markets
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Type of e-Health
5.1.1 Electronic Health Records
5.1.2 Health Information System
5.1.3 e-Prescribing
5.1.4 Clinical Decision Support Systems
5.1.5 Telemedicine
5.1.6 Other Types of e-Health
5.2 By Type of Service
5.2.1 Monitoring Services
5.2.1.1 Vital Sign Monitoring
5.2.1.2 Special Monitoring
5.2.1.3 Adherence Monitoring
5.2.2 Diagnosis Services
5.2.3 Other Types of Services
5.3 By End User
5.3.1 Hospitals
5.3.2 Insurance Companies
5.3.3 Healthcare Consumers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Allscripts Healthcare Solutions, Inc.
6.1.2 athenahealth Inc.
6.1.3 Boston Scientific Corporation
6.1.4 Cerner Corporation
6.1.5 CompuMed Inc.
6.1.6 GE Healthcare
6.1.7 IBM
6.1.8 McKinsey & Company
6.1.9 Proteus Digital Health
6.1.10 Telecare Corporation
7. Market Opportunities and Future Trends
By Type of e-Health
- Electronic Health Records
Health Information System
e-Prescribing
Clinical Decision Support Systems
Telemedicine
Other Types of e-Health
By Type of Service
Monitoring Services
Vital Sign Monitoring
Special Monitoring
Adherence Monitoring
Diagnosis Services
Other Types of Services
By End User
Hospitals
Insurance Companies
Healthcare Consumers
Geography
North America
United States
Canada
Mexico - Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Drug Discovery Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the drug discovery market include the rising prevalence of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and upcoming patent expiration of blockbuster drugs.
The diverse range of diseases, primarily cardiovascular disease, infectious diseases, diabetes, and kidney-related complications, has a high prevalence, globally. Thus, the increasing prevalence of a diverse range of diseases among all age groups and its burden, globally, drives the demand for drug discovery and its market.
There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. Due to automation, multi-detector readers, imaging hardware and software, high-throughput screening is one of the most widely used drug discovery technologies.
In recent years, there has been a rising demand for specialty medicines that is expected to ultimately influence the small molecule drug discovery market in a positive manner, as most of the specialty medicines are small molecules.
The gradual rise in the healthcare expenditure regionally helps the new pharmaceutical technology advancement. Although with high expenditure, there is a need for redirecting the resources, the transition toward better usability of healthcare expenditure for drug development is under progress.
Scope of the Report
As per the scope of the report, drug discovery is a process, which aims at identifying a compound therapeutically useful in treating and curing diseases. Typically, a drug discovery effort addresses a biological target that has been shown to play a role in the development of the disease or starts from a molecule with interesting biological activities. In the recent past, drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming.
Key Market Trends
Biologics Drug is the Segment that is Expected to Grow Fastest under Drug Type
A biologic drug is a product that is produced from living organisms or contains components of living organisms. Biologic drugs include a wide variety of products derived from human, animal, or microorganisms. Biologic drugs are used for the treatment of numerous diseases and conditions and are the most advanced therapies available. Biologic treatments are for autoimmune diseases, which include the treatments for rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn’s disease, and a range of related disorders, and have continued to see increasing usage across geographies. The biologic drugs are expected to be fueled by innovations in oncology, autoimmune, and diabetes treatments, with particular important opportunities for biologics in the oncology and autoimmune sectors.
The increasing applications of small molecule drugs for the treatment of chronic diseases are leading to the increased demand for these drugs in the market. Moreover, due to the aforementioned factors, small molecule drugs dominate the biologics in the current healthcare market.
Asia-Pacific Holds the Fastest Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia Pacific is the fastest-growing region, due to the presence of skilled labor at an affordable cost, the rise in disposable income, and favorable government policies that are contributing to the market growth. There has also been phenomenal growth in the outsourcing companies in the Chinese region, over the last decade, which has complemented the restructuring of the R&D that has taken place. Thus, owing to the large deals of pharmaceutical companies and more number of research being done, the market for drug discovery is expected to grow.
Competitive Landscape
The market studied has various pharmaceutical companies that are investing billions of dollars in artificial intelligence (AI), in order to make the drug discovery process significantly faster and cost efficient. The pharmaceutical and biotech companies are increasing their collaborations with contract development and manufacturing organizations; thus, playing a crucial role in the development and innovation of new drugs.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of a Diverse Range of Diseases
4.2.2 Technological Advancements and Innovations
4.2.3 Increasing Healthcare Expenditure
4.2.4 Patent Expiration of Blockbuster Drugs
4.3 Market Restraints
4.3.1 Huge Capital Investment with Low-profit Margins
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Drug Type
5.1.1 Small Molecule Drug
5.1.2 Biologic Drug
5.2 By Technology
5.2.1 High Throughput Screening
5.2.2 Biochips
5.2.3 Bioinformatics
5.2.4 Pharmacogenomics and Pharmacogenetics
5.2.5 Combinatorial Chemistry
5.2.6 Nanotechnology
5.2.7 Spectroscopy
5.2.8 Metabolomics
5.2.9 Other Technologies
5.3 By Service
5.3.1 Drug Metabolism and Pharmacokinetics (DMPK) Services
5.3.2 Pharmaceutical Services
5.3.3 Chemical Services
5.3.4 Biological Services
5.4 By End User
5.4.1 Research Institutes
5.4.2 Pharmaceutical Companies
5.4.3 Contract Research Organizations(CROs)
5.4.4 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 United Kingdom
5.5.2.2 Germany
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 GlaxoSmithKline PLC
6.1.3 Merck & Co. Inc.
6.1.4 Agilent Technologies Inc.
6.1.5 Eli Lilly and Company
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Bayer AG
6.1.8 Abbott
6.1.9 AstraZeneca PLC
6.1.10 Shimadzu Corp.
7. Market Opportunities and Future Trends
By Drug Type
- Small Molecule Drug
Biologic Drug
By Technology
High Throughput Screening
Biochips
Bioinformatics
Pharmacogenomics and Pharmacogenetics
Combinatorial Chemistry
Nanotechnology
Spectroscopy
Metabolomics
Other Technologies
By Service
Drug Metabolism and Pharmacokinetics (DMPK) Services
Pharmaceutical Services
Chemical Services
Biological Services
By End User
Research Institutes
Pharmaceutical Companies
Contract Research Organizations(CROs)
Other End Users - Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America